| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $21.3M | +25.3% |
| SG&A Expense | $26.8M | +33.2% |
| Operating Income | -$48.1M | -29.6% |
| Net Income | -$43.9M | -25.8% |
| EPS (Basic) | -$1.79 | -17.8% |
| EPS (Diluted) | -$1.79 | -17.8% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $9.6M | -27.0% |
| Current Assets | $10.1M | -29.7% |
| Total Assets | $30.2M | -13.4% |
| Current Liabilities | $9.5M | +44.6% |
| Total Liabilities | $9.8M | +21.9% |
| Stockholders' Equity | $20.4M | -24.0% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$15.3M | +32.2% |
| Capital Expenditures | $1.4M | -59.8% |
| Investing Cash Flow | -$1.4M | +59.8% |
| Financing Cash Flow | $13.1M | -41.0% |
| Free Cash Flow | -$16.7M | +36.0% |